Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism.

Sugie et al. (2005) ran a randomized trial with autistic children. Half got the SSRI fluvoxamine; half got placebo.

Doctors tracked overall autism severity and language skills. They also checked each child’s serotonin-transporter gene type (long or short allele).

Fluvoxamine beat placebo overall. The twist: gene type steered the gains.

Kids with the long allele improved on global scores. Kids with the short allele improved most in expressive language.

Gillberg et al. (1983) first spotted chemical clues in spinal fluid, hinting that serotonin biology matters in autism. Yoko’s team moved that idea forward by linking a specific gene to real drug response.

Jiao et al. (2012) tried to predict autism severity with 29 gene snippets. Their model was only 67 % accurate. Yoko’s single-gene split is simpler and tied to a clear treatment choice.

Tuzzi (2009) mapped odd grammar patterns in written texts from autistic people. Yoko shows a pill can actually shift spoken language—at least for short-allele carriers—turning static description into possible intervention.

If you work with autistic clients who take or may take fluvoxamine, ask the prescriber about 5-HTTLPR testing. A quick gene check can tell you whether to watch for broad gains (long allele) or language leaps (short allele). Pair the data with your ABA probes so you can celebrate the right milestones first.